NuGEN and Integrated Sciences in partnership with MHTP Medical Genomics Facility recently offered a Next-Gen Sequencing Grant to facilitate translational research. This grant provides the chance for researchers to utilize NuGEN technology and MHTP Medical Genomics Facility sequencing experience. With a total of 96 grant applications, we are pleased to announce the winner of this grant is Dr Amanda Smith from the University of Queensland Diamantina Institute.

Winning Abstract Title: MEK Inhibitor Resistance in Acute Myeloid Leukaemia
NuGEN Kit: Ovation Cancer Panel Target Enrichment System

Winner Biography: Dr. Amanda Smith received her PhD from the University of Newcastle in March 2014. Her PhD investigated the role of a tumour suppressor, protein phosphatase 2A, in mutant receptor tyrosine kinase driven acute myeloid leukaemia (AML). She took her first post-doctoral position in Dr. Andrew Moore’s research group at The University of Queensland with a strong focus on drug development for paediatric acute myeloid leukaemia. Here, she has further developed laboratory and personnel management skills and supervised a number of undergraduate and graduate students. Dr. Smith has a particular interest in the mechanisms that drive resistance to therapies utilised to treat AML, including novel therapies in development. In the future, Dr. Smith has the ambition to establish her own research program to investigate mechanisms of resistance to emerging therapeutic strategies with a focus on novel assays to detect and monitor disease for the presence of resistance.

Dr Amanda Smith